Ono type DX Breast Recurrence Score Test
Oncotype DX is a clinically validated multigene assay for predicting the likely benefit of chemotherapy in this patient population and is uniquely available from the current supplier on the global market.
Buyer
Leeds Teaching Hospitals NHS Trust
Value
£337,500
Published
26 Oct 2026
Closes
30 Jun 2026
Procurement details
Source
Contracts Finder
Region
United Kingdom
Procurement method
Selective
Category
Goods
Contract starts
30 Jun 2026
Contract ends
30 Jun 2028
CPV classifications
85111800
Pathology services
Lots
Lot default Ono type DX Breast Recurrence Score Test
£405,000
Oncotype DX is a clinically validated multigene assay for predicting the likely benefit of chemotherapy in this patient population and is uniquely available from the current supplier on the global market.
Delivery: British Oversea Territories, Channel Islands, Europe, Isle of Man, Rest of the World, United Kingdom
Documents
Unlock document linkAwarded contract notice on Contracts Finder
26 Oct 2026
Awarded contract notice on Contracts Finder
Award notice · Web page
Awarded contract notice on Contracts Finder
26 Oct 2026
Awarded contract notice on Contracts Finder
Award notice · Web page
Signed Paper work
Not provided
Signed Paper work
Contains public sector information licensed under the Open Government Licence v3.0.